Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

When is enough, enough? The correlation between once-daily basal insulin doses to the fasting plasma glucose in type 2 diabetes.

King AB.

Endocr Pract. 2013 Jul-Aug;19(4):735-6. doi: 10.4158/EP12094.LT. No abstract available.

PMID:
23512401
2.

Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.

Blonde L, Merilainen M, Karwe V, Raskin P; TITRATE Study Group.

Diabetes Obes Metab. 2009 Jun;11(6):623-31. doi: 10.1111/j.1463-1326.2009.01060.x.

PMID:
19515182
4.

A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.

Marbury TC, Schwartz S, Rosenberg MA, Jariwala N, Becker RH, Johnston PS.

Exp Clin Endocrinol Diabetes. 2008 May;116(5):282-8. doi: 10.1055/s-2007-1022521.

PMID:
18484560
5.
6.

Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).

Abraira C, Henderson WG, Colwell JA, Nuttall FQ, Comstock JP, Emanuele NV, Levin SR, Sawin CT, Silbert CK.

Diabetes Care. 1998 Apr;21(4):574-9.

PMID:
9571345
9.

Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in type 2 diabetes.

Bolli GB, Lucidi P, Porcellati F, Fanelli CG.

Diabetes Care. 2011 May;34 Suppl 2:S220-4. doi: 10.2337/dc11-s224. No abstract available.

10.

First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia.

Tsai ST, Pathan F, Ji L, Yeung VT, Chadha M, Suastika K, Son HS, Tan KE, Benjasuratwong Y, Nguyen TK, Iqbal F.

J Diabetes. 2011 Sep;3(3):208-16. doi: 10.1111/j.1753-0407.2011.00137.x.

13.

Type 2 diabetes mellitus--guidelines for initiating insulin therapy.

Yeap BB.

Aust Fam Physician. 2007 Jul;36(7):549-53.

14.

Fasting plasma glucose after intensive insulin therapy predicted long-term glycemic control in newly diagnosed type 2 diabetic patients.

Liu J, Liu J, Fang D, Liu L, Huang Z, Wan X, Cao X, Li Y.

Endocr J. 2013;60(6):725-32. Epub 2013 Feb 20.

15.

Is basal insulin always the first choice for initiation of insulin therapy in type 2 diabetic patients?

Mannucci E, Monami M, Masotti G, Marchionni N.

Exp Clin Endocrinol Diabetes. 2007 May;115(5):339-40. No abstract available.

PMID:
17516300
16.

Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus.

Malone JK, Woodworth JR, Arora V, Yang H, Campaigne BN, Hallé JP, Yale JF, Grossman LD.

Clin Ther. 2000 Feb;22(2):222-30.

PMID:
10743981
17.

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA.

Diabetes Care. 1996 Jun;19(6):580-6.

PMID:
8725855
18.

Improved insulin sensitivity and metabolic control in type 2 diabetes does not influence plasma homocysteine.

Pouwels MJ, Den Heijer M, Blom HJ, Tack CJ, Hermus AR.

Diabetes Care. 2003 May;26(5):1637-9. No abstract available.

PMID:
12716838
19.

Comparison of thrice daily 'high' vs. 'medium' premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes.

Ejskjaer N, Rasmussen M, Kamp N, Lindholm A, Christiansen JS.

Diabetes Obes Metab. 2003 Nov;5(6):438-45.

PMID:
14617230
20.

Influence of exogenous insulin on C-peptide levels in subjects with type 2 diabetes.

Albareda M, Rigla M, Rodríguez-Espinosa J, Caballero A, Chico A, Cabezas R, Carreras G, Pérez A.

Diabetes Res Clin Pract. 2005 Jun;68(3):202-6. Epub 2004 Dec 8.

PMID:
15936461

Supplemental Content

Support Center